In the Margins

Sequoia Fund manager details Valeant experience

March 1, 2016

By Barron's

In its annual report, Sequoia Fund manager Ruane, Cuniff & Goldfarb has vented about Valeant Pharmaceuticals' recent stock plunge, though it offers an optimistic outlook for the stock. The letter outlines how much Valeant’s relationship with affiliated pharmacy Philidor wreaked havoc for the fund company. Read the original story from Barron's.

 

 

Most Read

Top of the Agenda - Regulatory
SEC finalizes fair valuation rule

The Securities and Exchange Commission on Thursday adopted a new rule on fund valuation practices, the first comprehensive update in 50 years. Rule 2a-5 will permit ...